Cellectis S.A. (CLLS)
1.44
0.06 (4.35%)
At close: Apr 22, 2025, 3:59 PM
1.40
-2.85%
After-hours: Apr 22, 2025, 04:18 PM EDT
4.35% (1D)
| Bid | 1.32 |
| Market Cap | 144.42M |
| Revenue (ttm) | 41.51M |
| Net Income (ttm) | -36.76M |
| EPS (ttm) | -0.41 |
| PE Ratio (ttm) | -3.51 |
| Forward PE | -1.52 |
| Analyst | Buy |
| Ask | 1.52 |
| Volume | 42,716 |
| Avg. Volume (20D) | 357,063 |
| Open | 1.38 |
| Previous Close | 1.38 |
| Day's Range | 1.37 - 1.45 |
| 52-Week Range | 1.10 - 3.38 |
| Beta | 3.38 |
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 24, 2015
Employees 216
Stock Exchange NASDAQ
Ticker Symbol CLLS
Website https://www.cellectis.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CLLS stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 316.67% from the latest price.
Stock ForecastsNext Earnings Release
Cellectis S.A. is scheduled to release its earnings on May 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
+12.2%
Cellectis shares are trading higher after the comp...
Unlock content with
Pro Subscription
9 months ago
+0.49%
Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
